Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. by He, Jiang et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Medicine Faculty Publications Medicine
5-17-2017
Risk Factors for Heart Failure in Patients With
Chronic Kidney Disease: The CRIC (Chronic






See next page for additional authors
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs
Part of the Cardiology Commons, and the Cardiovascular Diseases Commons
This Journal Article is brought to you for free and open access by the Medicine at Health Sciences Research Commons. It has been accepted for
inclusion in Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
APA Citation
He, J., Shlipak, M., Anderson, A., Roy, J., Feldman, H., Kallem, R., Kanthety, R., Kusek, J., Ojo, A., Rahman, M., Ricardo, A., Soliman,
E., Wolf, M., Zhang, X., Raj, D., & Hamm, L. (2017). Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The
CRIC (Chronic Renal Insufficiency Cohort) Study.. Journal of American Heart Association, 6 (5). http://dx.doi.org/10.1161/
JAHA.116.005336
Authors
Jiang He, Michael Shlipak, Amanda Anderson, Jason A Roy, Harold I Feldman, Radhakrishna Reddy Kallem,
Radhika Kanthety, John W Kusek, Akinlolu Ojo, Mahboob Rahman, Ana C Ricardo, Elsayed Z Soliman,
Myles Wolf, Xiaoming Zhang, Dominic Raj, and Lee Hamm
This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/
977
Risk Factors for Heart Failure in Patients With Chronic Kidney
Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
Jiang He, MD, PhD; Michael Shlipak, MD, MPH; Amanda Anderson, PhD, MPH; Jason A. Roy, PhD; Harold I. Feldman, MD, MSCE;
Radhakrishna Reddy Kallem, MD; Radhika Kanthety, MD, MPH; John W. Kusek, PhD; Akinlolu Ojo, MD, PhD; Mahboob Rahman, MD;
Ana C. Ricardo, MD, MPH; Elsayed Z. Soliman, MD; Myles Wolf, MD, MMSc; Xiaoming Zhang, MS; Dominic Raj, MD; Lee Hamm, MD; for the
CRIC (Chronic Renal Insufficiency Cohort) Investigators*
Background-—Heart failure is common in patients with chronic kidney disease. We studied risk factors for incident heart failure
among 3557 participants in the CRIC (Chronic Renal Insufficiency Cohort) Study.
Methods and Results-—Kidney function was assessed by estimated glomerular filtration rate (eGFR) using serum creatinine,
cystatin C, or both, and 24-hour urine albumin excretion. During an average of 6.3 years of follow-up, 452 participants developed
incident heart failure. After adjustment for age, sex, race, and clinical site, hazard ratio (95% CI) for heart failure associated with 1
SD lower creatinine-based eGFR was 1.67 (1.49, 1.89), 1 SD lower cystatin C-based-eGFR was 2.43 (2.10, 2.80), and 1 SD higher
log-albuminuria was 1.65 (1.53, 1.78), all P<0.001. When all 3 kidney function measures were simultaneously included in the
model, lower cystatin C-based eGFR and higher log-albuminuria remained significantly and directly associated with incidence of
heart failure. After adjusting for eGFR, albuminuria, and other traditional cardiovascular risk factors, anemia (1.37, 95% CI 1.09,
1.72, P=0.006), insulin resistance (1.16, 95% CI 1.04, 1.28, P=0.006), hemoglobin A1c (1.27, 95% CI 1.14, 1.41, P<0.001),
interleukin-6 (1.15, 95% CI 1.05, 1.25, P=0.002), and tumor necrosis factor-a (1.10, 95% CI 1.00, 1.21, P=0.05) were all
significantly and directly associated with incidence of heart failure.
Conclusions-—Our study indicates that cystatin C-based eGFR and albuminuria are better predictors for risk of heart failure
compared to creatinine-based eGFR. Furthermore, anemia, insulin resistance, inflammation, and poor glycemic control are
independent risk factors for the development of heart failure among patients with chronic kidney disease. ( J Am Heart Assoc.
2017;6:e005336. DOI: 10.1161/JAHA.116.005336.)
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C ardiovascular disease (CVD) is the major cause ofpremature death in patients with chronic kidney disease
(CKD).1 Several prospective cohort studies have documented
an increased risk of CVD, including heart failure, in patients
with CKD.2–4 For example, Dhingra and colleagues reported
that individuals with creatinine-based estimated glomerular
filtration rate (eGFR) <60 mL/min per 1.73 m2 had a 2-fold
increased risk of heart failure compared with those with eGFR
≥60 in a cohort of 10 181 participants followed up for
10 years.3 Reduced creatinine-based eGFR and increased
proteinuria measured by dipstick were significantly associated
with increased risk of heart failure in a population-based
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longitudinal study with 1 526 437 patients identified from
province-wide laboratory data from Alberta, Canada.4 How-
ever, the association of severity of CKD measured by
creatinine-based eGFR, cystatin C-based eGFR, and 24-hour
urine albumin with heart failure has not been well examined
among patients with CKD. In addition, the contribution of
novel CVD risk factors to the excess risk of heart failure
among patients with CKD has not been well investigated.
We aimed to compare the strengths of associations among
creatinine-based eGFR, cystatin C-based eGFR, and 24-hour
urine albumin and incident heart failure. In addition, we
investigated the association of traditional and novel CVD risk
factors with heart failure in patients with CKD.
Methods
Study Participants
The CRIC (Chronic Renal Insufficiency Cohort) Study is an
ongoing multicenter cohort study among 3939 participants
who were enrolled between June 2003 and August 2008 from
7 clinical centers in the United States. The design of the study
and baseline characteristics of participants have been previ-
ously published.5 Briefly, men and women were eligible for the
study if they were between 21 and 74 years of age with an
eGFR between 20 and 70 mL/min per 1.73 m2 depending
upon age (age 21–44, eGFR 20–70; age 45–64, eGFR 20–60;
and age 65–74, eGFR 20–50). Patients who previously
received dialysis for ≥1 month or a kidney transplant, and
those with glomerulonephritis requiring immunosuppression,
cirrhosis, polycystic kidney disease, or severe heart failure,
defined as New York Heart Association class III or IV, were
excluded. For this analysis, we excluded 382 patients with a
self-reported history of physician-diagnosed heart failure.
Therefore, a total of 3557 participants were included in this
analysis.
The investigation conforms with the principles outlined in
the Declaration of Helsinki. Institutional review boards at all
participating institutions approved the study protocol, and all
participants provided written informed consent.
Baseline Measurements
A baseline medical history questionnaire was administered to
obtain information on demographic characteristics, lifestyle
risk factors, previous history of CVD, and use of medications.
Body weight, height, and waist circumference were measured
according to standard methods. Three seated blood pressure
(BP) measurements were obtained by trained and certified
staff after at least 5 minutes of quiet rest. Hypertension was
defined as mean BP ≥140/90 mm Hg or self-reported use of
antihypertensive medication.
Serum creatinine was measured using an enzymatic
method on an Ortho Vitros 950 and standardized to
isotope-dilution mass spectrometry traceable values. Cystatin
C, homocysteine, high-sensitive C-reactive protein, inter-
leukin-6, and tumor necrosis factor (TNF)-a were measured
by the particle-enhanced immunonephelometry method. Fib-
rinogen was measured using the immunochemical reaction
method. eGFR was calculated according to the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration) crea-
tinine equation, cystatin C equation, and creatinine-cystatin C
equation.6 A homeostasis model assessment (HOMA) was
calculated to evaluate insulin resistance using fasting serum
insulin and plasma glucose.7 Diabetes mellitus was defined as
a fasting plasma glucose ≥126 mg/dL, a nonfasting plasma
glucose ≥200 mg/dL, or self-reported use of anti-diabetes
mellitus medication. A 24-hour urine specimen was collected
in all participants and urinary albumin was measured by
radioimmunoassay. All laboratory measurements were con-
ducted at the CRIC Study central laboratory at the University
of Pennsylvania with stringent quality control.
Assessment of Outcomes
CRIC Study participants were followed annually by clinic visits
with interim telephone contact at 6 months. The primary
study outcome was incident heart failure over the time from
study entry to March 2012. Heart failure was identified by
asking study participants every 6 months if they were
hospitalized, and selected hospitals or healthcare systems
were queried for qualifying encounters. The first 30 discharge
codes were identified for all hospitalizations, and codes
relevant to heart failure resulted in retrieval of medical
records by study personnel for centralized adjudicated review.
At least 2 study physicians reviewed all possible heart failure
events using medical records and guidelines on clinical
symptoms, radiographic evidence of pulmonary congestion,
physical examination of the heart and lungs and, when
available, central venous hemodynamic monitoring data, and
echocardiographic imaging. Heart failure was confirmed when
both reviewers agreed on a probable or definite occurrence of
heart failure based on modified clinical Framingham criteria.8
Patients’ follow-up was censored at the time of heart failure,
death, withdrawal, loss to follow-up, or the end of the follow-
up period, whichever occurred first.
Statistical Analysis
To compare the relative strengths in predicting incident heart
failure, hazard ratios associated with 1 SD of creatinine-based
eGFR, cystatin-C-based eGFR, or log-transformed albuminuria
were assessed using Cox proportional hazards models after
adjustment for age, sex, race, and clinical site.9 In addition,
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these CKD markers were included in the multivariable Cox
proportional hazards models simultaneously. Age, sex, and
race were only moderately correlated with eGFR (r≤0.2) in the
CRIC participants. The assumption of proportionality was
tested using Schoenfeld residuals and interaction terms with
time for each exposure variable and covariate. No substantial
deviations from proportionality were observed.
The associations of baseline traditional and novel risk
factors with subsequent heart failure incidence were exam-
ined using multivariable Cox proportional hazards models.
Initial models were adjusted for age, sex, race, and clinical
site. For the multivariable analysis of traditional risk factors,
the backward elimination method was used, and only
covariates that were significant (P<0.05) were retained in
the final model. For the multivariable analysis of novel risk
factors, all variables retained in the final traditional risk factor
model were included as covariates. The log-transformation
was performed for risk factors that were not normally
distributed. Hazard ratios and 95% CI of heart failure
associated with categorical variables or 1 SD increase in
continuous variables were presented. All analyses were
conducted using SAS version 9.1 (SAS Institute Inc, Cary,
NC). All P-values were 2-sided, and statistical significance was
defined as P<0.05.
Results
Baseline characteristics of study participants by quartile of
creatinine and cystatin C-based eGFR are presented in
Table 1. Participants with lower creatinine and cystatin C-
based eGFR were more likely to be older, female, and black or
Hispanic; to have less than high school education and lower
physical activity and alcohol consumption, but higher current
smoking; to have higher prevalence of CVD, hypertension,
diabetes mellitus, and anemia; to have higher levels of body
mass index, waist circumference, systolic BP, HOMA-insulin
resistance, hemoglobin A1c (HbA1c), homocysteine, fibrino-
gen, high-sensitive C-reactive protein, interleukin-6, TNF-a,
and leukocyte count, and lower levels of high-density
lipoprotein- and low-density lipoprotein-cholesterol, and
hemoglobin.
Over 6.3 years of follow-up, the overall incidence of heart
failure was 21.7 per 1000 person-years. In general, the
incidence of heart failure was higher among individuals with
lower creatinine-based eGFR and cystatin C-based eGFR
(Figure A). However, this association was more consistent
with cystatin C-based eGFR, especially among those with a
creatinine-based eGFR less than 60 mL/min per 1.73 m2.
Likewise, the incidence of heart failure was higher among
individuals with lower creatinine-based eGFR and higher
albuminuria (Figure B). This association was more consistent
with albuminuria.
The descriptive statistics of creatinine-based eGFR, cys-
tatin C-based eGFR, and urine albumin, as well as their
correlation coefficients, are shown in Table 2. As anticipated,
creatinine-based eGFR and cystatin C-based eGFR are highly
correlated. All 3 measures of CKD were associated with
incident heart failure after adjusting for age, sex, race, and
clinical site (Table 3). In the multivariable model including
both creatinine-based eGFR and cystatin C-based eGFR
simultaneously, the association between lower cystatin C-
based eGFR and heart failure became stronger, while the
association between lower creatinine-based eGFR and heart
failure became inverse. In multivariable models including both
creatinine-based eGFR and albuminuria, or cystatin C-based
eGFR and albuminuria, the associations of creatinine-based
eGFR, cystatin C-based eGFR, and albuminuria with incident
heart failure remained significant. In multivariable models
including creatinine-based eGFR, cystatin C-based eGFR, and
albuminuria simultaneously, the associations of cystatin C-
based eGFR and albuminuria with incident heart failure
remained significant, while the association between crea-
tinine-based eGFR and heart failure became inverse.
After adjusting for age, sex, race, and clinical site, several
risk factors (ie, <high school education, history of CVD,
hypertension, and diabetes mellitus, higher levels of body
mass index, waist girth, systolic BP, cystatin C, and urine
albumin, and lower level of creatinine-cystatin C-based eGFR)
were significantly associated with higher incidence of heart
failure. Higher levels of physical activity, alcohol consumption,
and high-density lipoprotein-cholesterol were significantly
associated with lower incidence of heart failure (Table 4). In
the backward selection model, lesss than high school
education, history of CVD and diabetes mellitus, higher levels
of waist circumference, systolic BP, cystatin C, and urine
albumin remained significantly associated with higher risk of
incident heart failure.
In the demographic-adjusted model, anemia, HOMA-insulin
resistance, HbA1c, uric acid, homocysteine, fibrinogen, high-
sensitive C-reactive protein, interleukin-6, TNF-a, and leuko-
cyte count were significantly associated with increased risk of
incident heart failure while blood hemoglobin was significantly
associated with decreased risk of incident heart failure
(Table 5). After further adjustment for the significant tradi-
tional risk factors listed above, the associations of anemia,
hemoglobin, HOMA-insulin resistance, HbA1c, interleukin-6,
and TNF-a remained significantly associated with higher risk
of incident heart failure.
Discussion
Our study indicated that the incidence of heart failure is high
in patients with CKD. Incident heart failure was significantly
DOI: 10.1161/JAHA.116.005336 Journal of the American Heart Association 3






















higher among patients with lower eGFR and higher albumin-
uria. Cystatin C-based eGFR and albuminuria were stronger
predictors for subsequent risk of heart failure than creatinine-
based eGFR among patients with CKD. In addition to
traditional risk factors, anemia, HOMA-insulin resistance,
HbA1c, interleukin-6, and TNF-a were significantly associated
with increased risk of incident heart failure among patients
with CKD.
Table 1. Baseline Characteristics of Study Participants by Categories of Creatinine-Cystatin C-Based eGFR: the CRIC Study
Quartiles of eGFRCr─Cyst C (mL/min Per 1.73 m
2)
P-Values for
Group Differences≥60 (n=672) 45 to 59 (n=1021) 30 to 44 (n=1192) <30 (n=672)
Age, mean (SD), y 53.2 (10.7) 58.8 (10.6) 59.6 (11.1) 58.2 (11.2) <0.001
Male, n (%) 373 (55.5) 606 (59.4) 629 (52.8) 333 (49.6) <0.001
Race/ethnicity, n (%)
White 357 (53.1) 471 (46.1) 476 (39.9) 217 (32.3) <0.001
Black 239 (35.6) 398 (39.0) 505 (42.4) 291 (43.3)
Hispanic 38 (5.7) 110 (10.8) 173 (14.5) 139 (20.7)
Other 38 (5.7) 42 (4.1) 38 (3.2) 25 (3.7)
High school education, n (%) 624 (93.0) 850 (83.3) 887 (74.4) 463 (68.9) <0.001
Physical activity, mean (SD), MET/week 242.3 (165.7) 202.3 (129.9) 193.9 (152.2) 177.3 (136.9) <0.001
Current cigarette smoking, n (%) 65 (9.7) 115 (11.3) 162 (13.6) 121 (18.0) <0.001
Current alcohol consumption, n (%) 515 (76.6) 682 (66.8) 720 (60.4) 361 (53.7) <0.001
History of cardiovascular disease, n (%) 92 (13.7) 260 (25.5) 360 (30.2) 222 (33.0) <0.001
Hypertension, n (%) 435 (64.7) 904 (88.5) 1083 (90.9) 622 (92.6) <0.001
Diabetes mellitus, n (%) 184 (27.4) 447 (43.8) 632 (53.0) 382 (56.8) <0.001
Anemia*, n (%) 139 (20.8) 382 (37.6) 653 (55.1) 471 (70.4) <0.001
Body mass index, mean (SD), kg/m2 30.2 (6.5) 31.8 (7.6) 32.6 (7.9) 32.4 (8.5) <0.001
Waist circumference, mean (SD), cm 100.9 (15.1) 105.9 (17.4) 106.8 (17.5) 106.4 (18.7) <0.001
Systolic blood pressure, mean (SD), mm Hg 121.6 (18.5) 127.2 (20.6) 130.6 (22.8) 133.5 (24.0) <0.001
HDL-cholesterol, mean (SD), mg/dL 50.9 (16.8) 48.1 (15.2) 47.4 (15.7) 45.6 (14.4) <0.001
LDL-cholesterol, mean (SD), mg/dL 108.4 (32.2) 104.7 (34.6) 101.7 (35.3) 101.9 (39.4) <0.001
Hemoglobin, mean (SD), g/dL 13.6 (1.5) 13.0 (1.7) 12.3 (1.6) 11.7 (1.7) <0.001
HOMA-insulin resistance, median (IQR) 3.17 (2.11, 5.39) 4.12 (2.64, 7.02) 4.22 (2.60, 7.45) 4.40 (2.57, 7.60) <0.001
Hemoglobin A1c, mean (SD), % 6.19 (1.38) 6.57 (1.50) 6.76 (1.54) 6.73 (1.60) <0.001
Uric acid, mean (SD), mg/dL 6.12 (1.61) 7.06 (1.69) 7.68 (1.73) 8.28 (1.96) <0.001
Homocysteine, median (IQR), mg/dL 10.2 (8.6, 12.6) 12.8 (10.7, 15.3) 15.0 (12.5, 18.3) 17.8 (14.5, 22.0) <0.001
Fibrinogen, mean (SD), mg/dL 3.51 (0.85) 3.96 (1.03) 4.29 (1.20) 4.71 (1.37) <0.001
hsC-reactive protein, median (IQR), mg/L 1.51 (0.79, 3.59) 2.58 (1.10, 6.00) 2.89 (1.16, 7.10) 2.95 (1.11, 7.59) <0.001
Interleukin-6, median (IQR), pg/mL 1.09 (0.71, 1.82) 1.67 (1.10, 2.60) 2.08 (1.34, 3.34) 2.59 (1.64, 4.13) <0.001
Tumor necrosis factor-a, median (IQR), ng/mL 1.4 (1.0, 2.0) 1.9 (1.4, 2.7) 2.4 (1.8, 3.4) 3.2 (2.3, 4.2) <0.001
Leukocyte count, median (IQR), 109 cells/L 5.6 (4.7, 6.8) 6.1 (5.1, 7.4) 6.4 (5.3, 7.8) 6.7 (5.6, 8.1) <0.001
Creatinine, mean (SD), mg/dL 1.19 (0.21) 1.44 (0.22) 1.80 (0.33) 2.55 (0.58) <0.001
Cystatin C, mean (SD), mg/L 0.89 (0.14) 1.20 (0.15) 1.60 (0.22) 2.31 (0.42) <0.001
Urine albumin, median (IQR), g/24 h 0.01 (0.01, 0.05) 0.03 (0.01, 0.27) 0.11 (0.02, 0.80) 0.39 (0.06, 1.54) <0.001
Mean (SD), median (interquartile range), or number (percent). CRIC indicates Chronic Renal Insufficiency Cohort Study; eGFRCr─Cyst C, creatinine and cystatin C-based glomerular filtration
rate; HDL, high-density lipoprotein; hsC-reactive protein, high-sensitive C-reactive protein; HOMA, homeostasis model assessment; IQR, interquartile range; LDL, low-density lipoprotein;
MET, metabolic equivalent of task.
*Anemia was defined as hemoglobin <13 g/dL for men and <12 g/dL for women.
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These findings have important clinical significance because
CKD is highly prevalent in the general population and CVD,
including heart failure, is the leading cause of death among
patients with CKD.1 In the Framingham Heart Study, the
incidence of heart failure was 4.7 per 1000 person-years
among 3757 men and 4472 women aged 40 to 94 years who
were followed up from 1971 to 1996.10 The Cardiovascular
Lifetime Risk Pooling Project included 39 578 adults aged
45 years and older from 3 US cohort studies and reported a
heart failure incidence of 8.3 per 1000 person-years.11 In the
Multi-Ethnic Study of Atherosclerosis study, the incidence of
heart failure was 3.1 per 1000 person-years among 6814
participants aged 45 to 84 years.12 The incidence of heart
failure in our study participants is much higher than in these
studies conducted in the general population but similar to
studies in CKD populations.13 For example, the incidence of
heart failure was 23 per 1000 person-years in a community-
based cohort of 114 900 adults with CKD stages 3 to 4 in
Northern California.13 Our study documented a several-fold
increased incidence of heart failure among patients with CKD
relative to the general population.
In the Chronic Kidney Disease Prognosis Consortium
cohorts, decreased creatinine-based eGFR and increased
urinary albumin-to-creatinine ratio were independently asso-
ciated with all-cause and CVD mortality.1 Blecker and
colleagues reported that albuminuria was associated with
subsequent risk of heart failure in the Atherosclerosis Risk in
Communities Study.14 In addition, decreased cystatin C-based
eGFR and albuminuria independently contributed to the risk of
heart failure in the Atherosclerosis Risk in Communities
study.2 The independent associations of decreased creatinine-
based eGFR and increased urinary albumin-to-creatinine ratio
with incident heart failure were also observed in a large
population-based longitudinal study in Alberta, Canada.4 Our
study indicated that creatinine-based eGFR, cystatin C-based
eGFR, and albuminuria are all associated with incident heart
failure. However, when all 3 CKD measures were included in
the same model simultaneously, cystatin C-based eGFR and
albuminuria provided better prediction of incident heart
failure. It has been suggested in previous studies that cystatin
C improves the prediction of CVD mortality beyond creati-
nine.15 Our study also indicated that the association between
lower creatinine-based eGFR and heart failure became inverse
after adjustment for cystatin C-based eGFR. There are 2
alternate explanations for this finding. First, it is possible that
high multicollinearity between cystatin C-based eGFR and
creatinine-based eGFR results in a change of sign of the
regression parameter estimate for the latter. Second, after
adjustment for more precise GFR measurement (cystatin C-
based eGFR), non-GFR determinants of serum creatinine (ie,
muscle mass and nutritional status) were associated with
lower all-cause mortality and heart failure incidence.16,17
Our study found that less than a high school education,
history of CVD, diabetes mellitus, systolic BP, and waist
circumference were significantly and independently associ-
ated with increased risk of heart failure. These traditional risk
factors have been associated with increased risk of heart
failure among the general population in previous cohort
studies.18
Anemia is common among patients with CKD and is
associated with increased risk of CVD in this population.19,20
In addition, anemia is frequent among patients with heart
failure and is associated with adverse outcomes and high
mortality among these patients.20 Our study indicated that
baseline anemia is a significant and independent risk factor
for subsequent risk of heart failure among patients with CKD.
Furthermore, there is an inverse association between blood
































































Figure. Incidence of heart failure among patients with chronic
kidney disease by creatinine-based eGFR, cystatin C-based eGFR,
and 24-hour urine albumin: the CRIC (Chronic Renal Insufficiency
Cohort) Study. A, Incidence of heart failure by creatinine-based
eGFR and cystatin C-based eGFR; (B) Incidence of heart failure by
creatinine-based eGFR and albuminuria. eGFR indicates estimated
glomerular filtration rate.
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several clinical trials have shown that treatment of anemia
among patients with CKD does not reduce CVD outcomes,
including heart failure.21–23 Anemia could be a comorbid
condition or common underlying cause of CKD and heart
failure.24,25 Future studies should examine whether the
prevention of anemia in patients with CKD will reduce the
risk of incident heart failure.
Inflammatory biomarkers have been associated with
increased risk of heart failure in community-based cohort
studies.26,27 Our study provides novel findings on the
association between systemic inflammation and risk of
heart failure among patients with CKD. After adjustment for
age, sex, and race, it was determined that multiple
inflammatory biomarkers, including fibrinogen, high-sensitive
C-reactive protein, interleukin-6, TNF-a, and leukocyte
count, were all significantly associated with incident heart
failure. After additional adjustment for established CVD risk
factors, interleukin-6 and TNF-a were significantly and
independently associated with risk of heart failure. These
data suggest that inflammation might play an important
role in the development of heart failure among patients
with CKD.
Table 2. Descriptive Statistics and Correlation Coefficients of Creatinine-Based eGFR, Cystatin C-Based eGFR, and 24-Hour Urine
Albumin
Mean (SD) Media (IQR)
Correlation Coefficients (P-Values)
Creatinine-Based
eGFR Cystatin C-Based eGFR Albuminuria Log-Albuminuria
Creatinine-based eGFR,
mL/min per 1.73 m2
44.9 (15.1) 43.8 (33.5, 54.7) 1.00 0.826 (<0.001) 0.202 (<0.001) 0.265 (<0.001)
Cystatin C-based eGFR,
mL/min per 1.73 m2
53.3 (23.7) 48.9 (35.3, 67.5) 1.00 0.242 (<0.001) 0.314 (<0.001)
Albuminuria, g/24 h 0.68 (1.59) 0.06 (0.01, 0.55) 1.00 0.924 (<0.001)
Log-albuminuria, g/24 h* 0.33 (0.52) 0.06 (0.01, 0.44) 1.00
Creatinine-based eGFR ranged from 6.9 to 110.4 mL/min per 1.73 m2; cystatin C-based eGFR ranged from 11.1 to 150.0 mL/min per 1.73 m2; albuminuria ranged from 0 to 18.5 g/
24 h; and log-albuminuria ranged from 0 to 2.97 g/24 h. eGFR indicates estimated glomerular filtration rate; IQR, interquartile range.
*Log-albuminuria=Log (urine albumin g/24 h+1).
Table 3. Multivariable-Adjusted Hazard Ratios (95% CI) of Congestive Heart Failure Associated With 1 SD of Creatinine-Based
eGFR, Cystatin C-Based eGFR, and Log-Transformed 24-Hour Urine Albumin
Hazard Ratio (95% CI) P-Value
1 SD decrease in creatinine-based eGFR (15.1 mL/min 1.73 m2)
Age, sex, and race adjusted 1.67 (1.49, 1.89) <0.001
Age, sex, race, and cystatin C-based eGFR adjusted 0.78 (0.65, 0.93) 0.006
Age, sex, race, and urine albumin adjusted 1.40 (1.23, 1.59) <0.001
Age, sex, race, cystatin C-based eGFR, and urine albumin adjusted 0.77 (0.65, 0.92) 0.005
1 SD decrease in cystatin C-based eGFR (23.8 mL/min)
Age, sex, and race adjusted 2.43 (2.10, 2.80) <0.001
Age, sex, race, and creatinine-based eGFR adjusted 3.04 (2.45, 3.78) <0.001
Age, sex, race, and urine albumin adjusted 2.01 (1.73, 2.34) <0.001
Age, sex, race, creatinine-based eGFR, and urine albumin adjusted 2.52 (2.02, 3.15) <0.001
1 SD increase in log-albuminuria (0.5 g/24 h)
Age, sex, and race adjusted 1.65 (1.53, 1.78) <0.001
Age, sex, race, and creatinine-based eGFR adjusted 1.56 (1.44, 1.69) <0.001
Age, sex, race, and cystatin C-based eGFR adjusted 1.45 (1.34, 1.58) <0.001
Age, sex, race, creatinine-based eGFR, and cystatin C-based eGFR adjusted 1.45 (1.34, 1.58) <0.001
All analyses stratified by clinical site. eGFR indicates estimated glomerular filtration rate; log-albuminuria, log (urine albumin g/24 h+1).
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The association between diabetes mellitus and heart
failure has been well described, with diabetes mellitus
increasing the risk of heart failure by 2- to 6-fold.28 Recent
population-based cohort studies reported that insulin resis-
tance, calculated from insulin and glucose, was associated
with increased risk of heart failure.29,30 Our study indicates
Table 5. Multivariable-Adjusted Hazard Ratios (95% CI) of Congestive Heart Failure Associated With Novel CVD Risk Factors
Variables*
Age-Sex-Race Adjusted Multivariable-Adjusted†
Hazard Ratio (95% CI) P-Value Hazard Ratio (95% CI) P-Value
Anemia 2.19 (1.79, 2.69) <0.001 1.37 (1.09, 1.72) 0.006
Blood hemoglobin, 1.8 g/dL 0.61 (0.55, 0.68) <0.001 0.85 (0.75, 0.96) 0.007
Log HOMA-insulin resistance, 0.67 unit 1.41 (1.29, 1.53) <0.001 1.16 (1.04, 1.28) 0.006
Hemoglobin A1c, 1.5% 1.54 (1.43, 1.65) <0.001 1.27 (1.14, 1.41) <0.001
Uric acid, 1.9 mg/dL 1.21 (1.09, 1.33) <0.001 1.05 (0.94, 1.17) 0.37
Log homocysteine, 0.33 mg/dL 1.23 (1.11, 1.36) <0.001 0.90 (0.79, 1.03) 0.11
Fibrinogen, 1.2 mg/dL 1.55 (1.42, 1.68) <0.001 1.06 (0.95, 1.18) 0.30
Log hsC-reactive protein, 0.87 mg/L 1.18 (1.08, 1.29) <0.001 1.07 (0.97, 1.18) 0.20
Log interleukin-6, 0.66 pg/mL 1.30 (1.22, 1.39) <0.001 1.15 (1.05, 1.25) 0.002
Log tumor necrosis factor-a, 0.50 ng/mL 1.27 (1.18, 1.36) <0.001 1.10 (1.00, 1.21) 0.05
Log leukocyte count, 0.269109 cells/L 1.28 (1.17, 1.40) <0.001 1.07 (0.97, 1.19) 0.17
All analyses stratified by clinical site. CVD indicates cardiovascular disease; eGFRCr─Cyst C, creatinine and cystatin C-based glomerular filtration rate; HOMA, homeostasis model
assessment; hsC-reactive protein, high-sensitive C-reactive protein.
*Binary variable or 1 SD.
†Adjusted for age, sex, race, education, history of cardiovascular disease, diabetes mellitus, systolic blood pressure, waist circumference, serum cystatin C, log-urine albumin, and
eGFRCr─Cyst C.
Table 4. Multivariable-Adjusted Hazard Ratios (95% CI) of Congestive Heart Failure Associated With Established CVD Risk Factors
Variables*
Age-Sex-Race-Adjusted Multivariable-Adjusted†
Hazard Ratio (95% CI) P-Value Hazard Ratio (95% CI) P-Value
<High-school education 1.75 (1.39, 2.19) <0.001 1.47 (1.15, 1.87) 0.002
Physical activity, 147.5 MET/week 0.80 (0.71, 0.90) <0.001
Current cigarette smoking 1.24 (0.95, 1.62) 0.11
Current alcohol consumption 0.75 (0.61, 0.91) 0.003
History of cardiovascular disease 4.72 (3.89, 5.73) <0.001 3.28 (2.67, 4.04) <0.001
Hypertension 2.85 (1.80, 4.50) <0.001
Diabetes mellitus 3.04 (2.46, 3.76) <0.001 1.71 (1.35, 2.16) <0.001
Body mass index, 7.7 kg/m2 1.35 (1.24, 1.47) <0.001
Waist circumference, 17.4 cm 1.42 (1.30, 1.56) <0.001 1.28 (1.16, 1.42) <0.001
Systolic blood pressure, 22 mm Hg 1.45 (1.33, 1.58) <0.001 1.23 (1.10, 1.36) <0.001
HDL-cholesterol, 15.6 mg/dL 0.81 (0.72, 0.91) <0.001
LDL-cholesterol, 35.5 mg/dL 0.96 (0.87, 1.05) 0.36
Cystatin C, 0.5 mg/dL 1.73 (1.60, 1.88) <0.001 1.42 (1.29, 1.56) <0.001
Log urine albumin, 0.5 g/24 h 1.65 (1.53, 1.78) <0.001 1.22 (1.11, 1.34) <0.001
eGFRCr─Cyst C, 16.9 mL/min 1.73 m2 2.08 (1.83, 2.37) <0.001
All analyses stratified by clinical site. CVD indicates cardiovascular disease; eGFRCr─Cyst C, creatinine and cystatin C-based glomerular filtration rate; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; MET, metabolic equivalent of task.
*Binary variable or 1 SD.
†Multivariable model was selected by the backward selection method.
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that baseline HOMA-insulin resistance is significantly and
directly associated with increased risk of heart failure,
independent of multiple CVD risk factors including diabetes
mellitus and central obesity. In addition, our study indicates
that HbA1c, an index of long-term glycemic control, is
significantly associated with incident heart failure, indepen-
dent of diabetes mellitus. These data suggest that diabetes
mellitus and metabolic risk factors played an important role in
the risk of heart failure among patients with CKD.
A few limitations of our study should be considered when
making conclusions. This is an observational study, which
prevents us from making any causal inference. Since heart
failure at baseline was assessed by self-report, it is possible
that some participants may have been incorrectly classified as
either having or not having heart failure. In addition, new
cases of heart failure were identified initially by hospitaliza-
tion. Therefore, participants who were diagnosed with heart
failure in an ambulatory care setting would be missed.
Furthermore, the diagnosis of heart failure was made using
standard algorithms based on clinical, imaging, and laboratory
data that are validated in the general population, but not for
heart failure in the setting of CKD. Finally, the CRIC Study did
not further classify patients into systolic or diastolic heart
failure, which have different underlying mechanisms and
treatments.31,32
In conclusion, our study indicated that cystatin C-based
eGFR and albuminuria are better predictors for risk of heart
failure compared with creatinine-based eGFR among patients
with CKD. Furthermore, anemia, insulin resistance, inflamma-
tion, and poor glycemic control are independent risk factors
for the development of heart failure among patients with CKD.
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